Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BPN-14967 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (fasted condition) | EXPERIMENTAL | 10 mg BPN-14967 or placebo |
| Cohort 2 (fasted condition) | EXPERIMENTAL | 25 mg BPN-14967 or placebo |
| Cohort 3 (fasted condition) | EXPERIMENTAL | 50 mg BPN-14967 or placebo |
| Cohort 4 (fed condition) | EXPERIMENTAL | 10 mg BPN-14967 or placebo |
| Cohort 5 (high-fat fed condition) | EXPERIMENTAL | 10 mg BPN-14967 or placebo |
| Name | Type | Description |
|---|---|---|
| BPN-14967 | DRUG | BPN-14967 oral capsules |
| Placebo | DRUG | Oral capsules |
Inclusion Criteria: * The subject is male or female (not of childbearing potential), 18 to 65 years of age, inclusive, at screening. * The subject voluntarily consents to participate in this study and * provides written informed consent before the start of any study-specific procedures. * The subje...
BPN-14967 is an investigational small molecule being developed by Belite Bio, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and the completed trial evaluated its safety and tolerability.
BPN-14967 is being studied for use in healthy volunteers. The completed Phase 1 trial assessed the safety and tolerability of escalating doses of the drug in healthy adults. Its intended therapeutic use has not been specified.
BPN-14967 is being developed by Belite Bio, Inc, a biopharmaceutical company. The company's stock trades under the ticker symbol BLTE. Belite Bio is conducting clinical research on this investigational small molecule.
BPN-14967 is in Phase 1 clinical development. The Phase 1 trial, which has been completed, enrolled 40 healthy adult participants. The drug is investigational and has not been approved by regulatory authorities.
BPN-14967 has one completed Phase 1 clinical trial, identified as NCT04005807. The study, titled 'Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults,' was conducted in the United States with 40 participants aged 18 years and older.
Yes, the completed Phase 1 trial of BPN-14967 was randomized, double-blind, and controlled. The study enrolled 40 healthy volunteers and was conducted in the United States. The trial has been completed, and no active trials are currently listed.